Aerosol and nasal delivery of vaccines and antiviral drugs against seasonal and pandemic influenza (Q30388296)

21 June 2017

1 reference

title

Aerosol and nasal delivery of vaccines and antiviral drugs against seasonal and pandemic influenza (English)

1 reference

21 June 2017

0 references

0 references

Jonathan P Wong

1

1 reference

21 June 2017

Mary E Christopher

2

1 reference

21 June 2017

Satya Viswanathan

3

1 reference

21 June 2017

Glen Schnell

4

1 reference

21 June 2017

Xiaojiang Dai

5

1 reference

21 June 2017

Donald Van Loon

6

1 reference

21 June 2017

Eric R Stephen

7

1 reference

21 June 2017

language of work or name

1 reference

1 April 2010

1 reference

Expert Review of Respiratory Medicine

21 June 2017

1 reference

21 June 2017

4

1 reference

21 June 2017

2

1 reference

21 June 2017

171-177

1 reference

Epidemiology of cases of H5N1 virus infection in Indonesia, July 2005-June 2006.

21 June 2017

1 reference

Critically ill patients with 2009 influenza A(H1N1) infection in Canada.

21 January 2018

1 reference

Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico

21 January 2018

1 reference

Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia

21 January 2018

1 reference

Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness

21 January 2018

1 reference

Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome.

21 January 2018

1 reference

Seasonal inactivated influenza virus vaccines

21 January 2018

1 reference

Trivalent intranasal influenza vaccine, live

21 January 2018

1 reference

Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents

21 January 2018

1 reference

Live attenuated versus inactivated influenza vaccine in infants and young children.

21 January 2018

1 reference

Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial

21 January 2018

1 reference

Continuing increases in autism reported to California's developmental services system: mercury in retrograde

21 January 2018

1 reference

Inactivated influenza vaccine (IIV) in children <2 years of age: examination of selected adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) after thimerosal-free or thimerosal-containing vaccine

21 January 2018

1 reference

Antivirals for the treatment and prevention of epidemic and pandemic influenza

21 January 2018

1 reference

Antiviral agents active against influenza A viruses.

21 January 2018

1 reference

Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern

21 January 2018

1 reference

Amantadine-resistance among H5N1 avian influenza viruses isolated in Northern China

21 January 2018

1 reference

Oseltamivir resistance during treatment of influenza A (H5N1) infection

21 January 2018

1 reference

In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.

21 January 2018

1 reference

Detection of influenza A H1N1 and H3N2 mutations conferring resistance to oseltamivir using rolling circle amplification.

21 January 2018

1 reference

Influenza virus resistance to antiviral agents: a plea for rational use.

21 January 2018

1 reference

Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States

21 January 2018

1 reference

The first pandemic of the 21st century: a review of the 2009 pandemic variant influenza A (H1N1) virus.

21 January 2018

1 reference

Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B.

21 January 2018

1 reference

H1N1 pneumonitis treated with intravenous zanamivir

21 January 2018

1 reference

Zanamivir-resistant influenza viruses with a novel neuraminidase mutation

21 January 2018

1 reference

Use of ribavirin to treat influenza.

21 January 2018

1 reference

MegaRibavirin aerosol for the treatment of influenza A virus infections in mice

21 January 2018

1 reference

Nucleic acid-based antiviral drugs against seasonal and avian influenza viruses.

21 January 2018

1 reference

Antiviral role of toll-like receptor-3 agonists against seasonal and avian influenza viruses

21 January 2018

1 reference

Activation of toll-like receptor signaling pathway for protection against influenza virus infection

21 January 2018

1 reference

Augmented lung inflammation protects against influenza A pneumonia.

21 January 2018

1 reference

A novel influenza A (H1N1) vaccine in various age groups.

21 January 2018

1 reference

H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment.

21 January 2018

1 reference

Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work.

21 January 2018

1 reference

Continuous cell lines as a production system for influenza vaccines.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERS.10.15

1 reference

21 June 2017

1 reference